An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer

Oncology

Volumn 59, Issue 2, 2000, Pages 166-173

  Nishimura, Reiki ^a   Nagao, Kazuharu ^a   Miyayama, Haruhiko ^a   Matsuda, Masakazu ^a   Baba, Kenichirou ^a   Matsuoka, Yukio ^a   Yamashita, Hiroya ^a   Fukuda, Makoto ^a   Mizumoto, Takao ^a   Hamamoto, Rieko ^a  

^a KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

Breast cancer; Interleukin 6; Medroxyprogesterone acetate; Performance status

Indexed keywords

INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CACHEXIA; CANCER RECURRENCE; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL ASSESSMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; PERFORMANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0033832167     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012155     Document Type: Article

References (27)

1. Ganzina F: High-dose medroxyprogesterone acetate treatment in advanced breast cancer. A review. Tumori 1979;65:563.
2. Tominaga T, Izuo M, Nomura Y, et al: Oral high-dose medroxyprogesterone acetate in the treatment of advanced and recurrent breast cancer: A dose-response evaluation. Jpn J Cancer Chemother 1982;9:1994-2004.
3. Gallegher CJ, Cairnduff F, Smith IE: High-dose versus low-dose medroxyprogesterone acetate: A randomized trial in advanced breast cancer. Eur J Cancer Clin Oncol 1987;23: 1900-1985.
4. Nishimura R, Nagao K, Matsuda M, et al: Benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer with higher serum concentration. Breast Cancer 1995;2: 133-141.
5. Nishimura R, Nagao K, Matsuda M, Baba K, Matsuoka Y, Yamashita H, et al: Predictive value of serum medroxyprogesterone acetate concentration for response in advanced or recurrent breast cancer. Eur J Cancer 1997;33: 1407-1412.
6. Moldawer LL, Copeland EM: Proinflammatory cytokines, nutritional support, and the cachexia syndrome: Interactions and therapeutic options. Cancer 1997;79:1828-1839.
7. Noguchi Y, Yoshikawa T, Matsumoto A, et al: Are cytokines possible mediators of cancer cachexia? Surg Today 1996;26:467-475.
8. Strassmann GM, Fong M, Kenny JS, et al: Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest 1992;89:1681-1684.
9. Mantovani G, Macciò A, Lai P, Massa E, Ghiani M, Santona MC: Cytokine involvement in cancer anorexia/cachexia: Role of megesterol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncogen 1998;9: 99-106.
10. Kurebayashi J, Yamamoto S, Otsuki T, Sonoo H: Medroxyprogesterone acetate inhibits interleukin-6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: A possible mechanism of the anticachectic effect. Br J Cancer 1999;79:631-636.
11. Yamashita J, Hideshima T, Shirakusa T, Ogawa M: Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma. Cancer 1996;78:2346-2352.
12. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, et al: Evaluation of DNA polymerase-α as a prognostic predictor in early breast cancer smaller than 2 cm. Breast Cancer 1995;2:45-50.
13. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, et al: Correlation of S-phase fraction with response to chemotherapy in breast cancer. Jpn J Breast Cancer 1995;10:713-718.
14. Zhang XG, Klein B, Bataille R: Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74:11-13.
15. Scambia G, Testa U, Benedetti Pabici P, Foti E, Martucci R, Gadducci A, et al: Prognostic significance of interleukin-6 serum levels in patients with ovarian cancer. Br J Cancer 1995; 71:354-356.
16. Blay JY, Negrier S, Combaret V, Attali S, Goillet E, Merrouche Y, et al: Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992;52: 3317-3322.
17. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, Peng FK, et al: Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996;91:1417-1422.
18. Ástgeirsson KS, Ólafsdóttir K, Jónasson JG, Ögmundsdóttir HM: The effects of IL-6 on cell adhesion and E-cadherin expression in breast cancer. Cytokine 1998;10:720-728.
19. Fontanini G, Campani D, Roncella M, et al: Expression of interleukin-6 correlates with oestrogen receptor in human breast carcinoma. Br J Cancer 1999;80:579-584.
20. Classen S, Possinger K, Pelka-Fleischcr R, et al: Effect of medroxy-progesterone acetate on the proliferation and hormone receptor concent ration of human breast cancer cells. J Steroid Biochem Mol Biol 1993;45:315-319.
21. Hackenberg R, Hawighorst T, Filmer A, et al: Medroxyprogesterone acetate inhibits the proliferation of estrogen-and progesterone-receptor-negative MFM-223 human mammary cancer cells via the androgen receptor. Breast Cancer Res Treat 1993;25:217-224.
22. Birrell SN. Roder DM, Horsfall DJ, et al: Medroxyprogesterone acetate therapy in advanced breast cancer: The predictive value of androgen receptor expression. J Clin Oneol 1995;13: 1572-1577.
23. Lin VC, Ng EH, Aw SE, Tan MG, Ng EH, Chan VS, Ho GH: Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res 1999;5:395-403.
24. Hellman L, Yoshida K, Zumoff B, et al: The effect of medroxy-progesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab 1976;42:912-917.
25. Mattson W: Current status of high-dose progestin treatment in advanced breast cancer. Breast Cancer Res Treat 1983;3:231-235.
26. Oikawa T, Hiragun A, Yoshida Y, et al: Angiogenic activity of rat mammary carcinomas induced by 7,12-dimethylbenz(a)anthracene and its inhibition by medroxyprogesterone acetate: Possible involvement of antiangiogenic action of medroxyprogesterone acetate in its growth inhibition. Cancer Lett 1988;43:85-92.
27. Jikihara H, Terada N, Yamamoto R, et al: Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer. J Obstet Gynecol 1992;167: 207-211.